Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1993 1
1996 1
1997 1
1999 1
2002 2
2003 1
2005 1
2007 2
2008 4
2009 4
2010 6
2011 13
2012 13
2013 13
2014 15
2015 20
2016 24
2017 33
2018 31
2019 27
2020 44
2021 64
2022 48
2023 55
2024 63
2025 31

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

456 results

Results by year

Filters applied: . Clear all
Page 1
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Diseases and Injuries Collaborators. GBD 2021 Diseases and Injuries Collaborators. Lancet. 2024 May 18;403(10440):2133-2161. doi: 10.1016/S0140-6736(24)00757-8. Epub 2024 Apr 17. Lancet. 2024. PMID: 38642570 Free PMC article.
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.
Brody JD, Jørgensen J, Belada D, Costello R, Trněný M, Vitolo U, Lewis DJ, Karimi YH, Sureda A, André M, Wahlin BE, Lugtenburg PJ, Jiang T, Karagoz K, Steele AJ, Abbas A, Wang L, Risum M, Cordoba R. Brody JD, et al. Blood. 2025 Apr 10;145(15):1621-1631. doi: 10.1182/blood.2024026830. Blood. 2025. PMID: 39792928 Free PMC article. Clinical Trial.
Epcoritamab, a CD3CD20 bispecific antibody approved for R/R DLBCL after 2 therapy lines, has shown promising safety and efficacy in various combinations. ...Epcoritamab plus GemOx yielded deep, durable responses and favorable long-term outcomes in ASCT-ineligible …
Epcoritamab, a CD3CD20 bispecific antibody approved for R/R DLBCL after 2 therapy lines, has shown promising safety and effica …
Expression of Concern.
[No authors listed] [No authors listed] Addict Biol. 2024 Sep;29(9):e13437. doi: 10.1111/adb.13437. Addict Biol. 2024. PMID: 40179057 Free PMC article.
A. Ghaderi, H.R. Banafshe, N. Mirhosseini, M, Motmaen, F. Mehrzad, F. Bahmani, E. Aghadavod, M.A. Mansournia, R.J. Reiter, M-A. Karimi, and Z. Asemi, "The Effects of Melatonin Supplementation on Mental Health, Metabolic and Genetic Profiles in Patients Under …
A. Ghaderi, H.R. Banafshe, N. Mirhosseini, M, Motmaen, F. Mehrzad, F. Bahmani, E. Aghadavod, M.A. Mansournia, R.J. Reiter, M-A …
Communication Barriers Perceived by Nurses and Patients.
Norouzinia R, Aghabarari M, Shiri M, Karimi M, Samami E. Norouzinia R, et al. Glob J Health Sci. 2015 Sep 28;8(6):65-74. doi: 10.5539/gjhs.v8n6p65. Glob J Health Sci. 2015. PMID: 26755475 Free PMC article.
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Morris PG, et al. J Clin Oncol. 2013 Nov 1;31(31):3971-9. doi: 10.1200/JCO.2013.50.4910. Epub 2013 Oct 7. J Clin Oncol. 2013. PMID: 24101038 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: Patients received induction chemotherapy with R-MPV (five to seven cycles); those achieving a complete response (CR) received rdWBRT (23.4 Gy), and otherwise, standard WBRT was offered (45 Gy). ...Thirty-one patients (60%) achieved a CR after R …
PATIENTS AND METHODS: Patients received induction chemotherapy with R-MPV (five to seven cycles); those achieving a complete response …
456 results